Plasmin/plasminogen system in colorectal cancer

World Journal of Surgery

Volumn 26, Issue 7, 2002, Pages 767-771

  Berger, David H ^a,b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL SURFACE RECEPTOR; PLASMIN; PLASMINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN ACTIVATOR INHIBITOR 2; PROTEINASE; TUMOR MARKER; UROKINASE; UROKINASE RECEPTOR; PLASMINOGEN ACTIVATOR;

CANCER INVASION; CELL INVASION; CIRCULATION; COLORECTAL CARCINOMA; CONFERENCE PAPER; DISEASE ASSOCIATION; EXTRACELLULAR MATRIX; HUMAN; METASTASIS; PROGNOSIS; PROTEIN DEGRADATION; TUMOR CELL; ADENOCARCINOMA; COLORECTAL TUMOR; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW;

ADENOCARCINOMA; COLORECTAL NEOPLASMS; HUMANS; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; PLASMIN; PLASMINOGEN; PLASMINOGEN ACTIVATORS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 0036631895     PISSN: 03642313     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00268-002-4050-8     Document Type: Conference Paper

References (58)

1. Andreasen PA, Kjoller L, Christensen L, et al. The urokinase-type plasminogen activator system in cancer metastasis: a review. Int. J. Cancer 1997;72:1-22
2. Besser D, Verde P, Nagamie Y, et al. Signal transduction and the u-PA/u-PAR system. Fibrinolysis 1996;10:215-217
3. Schmitt M, Harbeck N, Thomssen C, et al. Clinical impact of the plasminogen activation system in tumor invasion and metastasis: prognostic relevance and target for therapy. Thromb. Haemost. 1997;78:285-296
4. Blasi F. Urokinase and urokinase receptor: a paracrine/autocrine system regulating cell migration and invasiveness. Bioessays 1993;15:105-111
5. Ploug M, Ellis V, Dano K. Ligand interaction between urokinase-type plasminogen activator and its receptor probed with 8-anilino-1-naphthalenesulfonate: evidence for a hydrophobic binding site exposed only on the intact receptor. Biochemistry 1994;33:8991-8997
6. Ploug M, Rahbek-Nielsen H, Ellis V, et al. Chemical modification of the urokinase-type plasminogen activator and its receptor using tetranitromethane: evidence for the involvement of specific tyrosine residues in both molecules during receptor-ligand interaction. Biochemistry 1995;34:12524-12534
7. Schmitt M, Wilhelm O, Janicke F, et al. Urokinase-type plasminogen activator (uPA) and its receptor (CD87): a new target in tumor invasion and metastasis. J. Obstet. Gynecol. 1995;21:151-165
8. Albo D, Berger DH, Vogel J, et al. Thrombospondin-1 and transforming growth factor beta-1 upregulate plasminogen activator inhibitor type 1 in pancreatic cancer. J. Gastrointest. Surg. 1999;3:411-417
9. Ploug M, Ronne E, Behrendt N, et al. Cellular receptor for urokinase plasminogen activator: carboxyl-terminal processing and membrane anchoring by glycosylphosphatidylinositol. J. Biol. Chem. 1991;266:1926-1933
10. Nielsen LS, Kellermann GM, Behrendt N, et al. A 55,000-60,000 Mr receptor protein for urokinase-type plasminogen activator: identification in human tumor cell lines and partial purification. J. Biol. Chem. 1988;263:2358-2363
11. Ploug M, Behrendt N, Lober D, et al. Protein structure and membrane anchorage of the cellular receptor for urokinase-type plasminogen activator. Semin. Thromb. Hemost. 1991;17:183-193
12. Dumler I, Petri T, Schleuning WD. Induction of c-fos gene expression by urokinase-type plasminogen activator in human ovarian cancer cells. FEBS Lett. 1994;343:103-106
13. Miles LA, Plow EF. Plasminogen receptors: ubiquitous sites for cellular regulation of fibrinolysis. Fibrinolysis 1988;2:61-71
14. Albo D, Berger DH, Rothman VL, et al. Role of urokinase plasminogen activator receptor in thrombospondin 1-mediated tumor cell invasion. J. Surg. Res. 1999;82:331-338
15. Albo D, Berger DH, Wang TN, et al. Thrombospondin-1 and transforming growth factor-beta 1 promote breast tumor cell invasion through up-regulation of the plasminogen/plasmin system. Surgery 1997;122:493-500
16. Markus G, Kohga S, Camiolo SM, et al. Plasminogen activators in human malignant melanoma. J. Natl. Cancer Inst. 1984;72:1213-1222
17. De Bruin PA, Griffioen G, Verspaget HW, et al. Plasminogen activators and tumor development in the human colon: activity levels in normal mucosa, adenomatous polyps, and adenocarcinomas. Cancer Res. 1987;47:4654-4657
18. De Bruin PA, Griffioen G, Verspaget HW, et al. Plasminogen activator profiles in neoplastic tissues of the human colon. Cancer Res. 1988;48:4520-4524
19. Skelly MM, Troy A, Duffy MJ, et al. Urokinase-type plasminogen activator in colorectal cancer: relationship with clinicopathological features and patient outcome. Clin. Cancer Res. 1997;3:1837-1840
20. Grondahl-Hansen J, Ralfkiaer E, Kirkeby LT, et al. Localization of urokinase-type plasminogen activator in stromal cells in adenocarcinomas of the colon in humans. Am. J. Pathol. 1991;138:111-117
21. Pyke C, Kristensen P, Ralfkiaer E, et al. Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas. Am. J. Pathol. 1991;138:1059-1067
22. Harvey SR, Sait SN, Xu Y, et al. Demonstration of urokinase expression in cancer cells of colon adenocarcinomas by immunohistochemistry and in situ hybridization. Am. J. Pathol. 1999;155:1115-1120
23. Costantini V, Sidoni A, Deveglia R, et al. Combined overexpression of urokinase, urokinase receptor, and plasminogen activator inhibitor-1 is associated with breast cancer progression: an immunohistochemical comparison of normal, benign, and malignant breast tissues. Cancer Res. 1996;56:1432-1439
24. Herszenyi L, Plebani M, Carraro P, et al. The role of cysteine and serine proteases in colorectal carcinoma. Cancer 1999;86:1135-1142
25. Taniguchi T, Kakkar AK, Tuddenham EG, et al. Enhanced expression of urokinase receptor induced through the tissue factor-factor VIIa pathway in human pancreatic cancer. Cancer Res. 1998;58:4461-4467
26. Wang SN, Miyauchi M, Koshikawa N, et al. Antigen expression associated with lymph node metastasis in gastric adenocarcinomas. Pathol. Int. 1994;44:844-849
27. Cantero D, Friess H, Deflorin J, et al. Enhanced expression of urokinase plasminogen activator and its receptor in pancreatic carcinoma. Thromb. Haemost. 1997;77:62-70
28. Park IK, Kim BJ, Goh YJ, et al. Co-expression of urokinase-type plasminogen activator and its receptor in human gastric-cancer cell lines correlates with their invasiveness and tumorigenicity. Int. J. Cancer 1997;71:867-873
29. Ganesh S, Sier CF, Heerding MM, et al. Urokinase receptor and colorectal cancer survival [letter]. Lancet 1994;344:401-402
30. Stephens RW, Nielsen HJ, Christensen IJ, et al. Plasma urokinase receptor levels in patients with colorectal cancer: relationship to prognosis. J. Natl. Cancer Inst. 1999;91:869-874
31. Suzuki S, Hayashi Y, Wang Y, et al. Urokinase type plasminogen activator receptor expression in colorectal neoplasms. Gut 1998;43:798-805
32. Taniguchi T, Lemoine NR, Kakkar AK. Urokinase receptor is a key player in tumour progression. Gut 1998;43:739-740
33. Sier CF, Verspaget HW, Griffioen G, et al. Imbalance of plasminogen activators and their inhibitors in human colorectal neoplasia: implications of urokinase in colorectal carcinogenesis. Gastroenterology 1991;101:1522-1528
34. Sier CF, Vloedgraven HJ, Ganesh S, et al. Inactive urokinase and increased levels of its inhibitor type 1 in colorectal cancer liver metastasis. Gastroenterology 1994;107:1449-1456
35. Bajou K, Noel A, Gerard RD, et al. Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nat. Med. 1998;4:923-928
36. Wei Y, Lukashev M, Simon DI, et al. Regulation of integrin function by the urokinase receptor. Science 1996;273:1551-1555
37. Stefansson S, Lawrence D. The serpin PAI-1 inhibits cell migration by blocking integrin avb3 binding to vitronectin. Nature 1996;383:441-443
38. Deng G, Curriden SA, Wang S, et al. Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release? AIDS 1996;10:1211-1219
39. Kanse SM, Kost C, Wilhelm OG, et al. The urokinase receptor is a major vitronectin-binding protein on endothelial cells. Exp. Cell Res. 1996;224:344-353
40. Abe J, Urano T, Konno H, et al. Larger and more invasive colorectal carcinoma contains larger amounts of plasminogen activator inhibitor type 1 and its relative ratio over urokinase receptor correlates well with tumor size. Cancer 1999;86:2602-2611
41. Aguirre Ghiso JA, Kovalski K, Ossowski L. Tumor dormancy induced by downregulation of urokinase receptor in human carcinoma involves integrin and MAPK signaling. J. Cell Biol. 1999;147:89-104
42. Mann B, Gelos M, Siedow A, et al. Target genes of b-catenin-T cell-factor/lymphoid-enhancer-factor signaling in human colorectal carcinomas. Proc. Natl. Acad. Sci. U.S.A. 1999;96:1603-1608
43. Besser D, Urich M, Sakaue M, et al. Urokinase-type plasminogen activator gene regulation by polyomavirus middle-T antigen. Oncogene 1995;11:2383-2391
44. Stacey KJ, Fowles LF, Colman MS, et al. Regulation of urokinase-type plasminogen activator gene transcription by macrophage colony-stimulating factor. Mol. Cell Biol. 1995;15:3430-3441
45. Besser D, Presta M, Nagamine Y. Elucidation of a signaling pathway induced by FGF-2 leading to uPA gene expression in NIH 3T3 fibroblasts. Cell Growth Differ. 1995;6:1009-1017
46. Marksitzer R, Stief A, Menoud PA, et al. Role of LFB3 in cell-specific cAMP induction of the urokinase-type plasminogen activator gene. J. Biol. Chem. 1995;270:21833-21838
47. Mars WM, Kim TH, Stolz DB, et al. Presence of urokinase in serum-free primary rat hepatocyte cultures and its role in activating hepatocyte growth factor. Cancer Res. 1996;56:2837-2843
48. Jeffers M, Rong S, Vande Woude GF. Enhanced tumorigenicity and invasion-metastasis by hepatocyte growth factor/scatter factor-met signalling in human cells concomitant with induction of the urokinase proteolysis network. Mol. Cell Biol. 1996;16:1115-1125
49. Lengyel E, Klostergaard J, Boyd D. Stimulation of urokinase expression by TNF-alpha requires the activation of binding sites for the AP-1 and PEA3 transcription factors. Biochim. Biophys. Acta 1995;1268:65-72
50. Lengyel E, Stepp E, Gum R, Boyd D. Involvement of a mitogen-activated protein kinase signaling pathway in the regulation of urokinase promoter activity by c-Ha-ras. J. Biol. Chem. 1995;270:23007-23012
51. Grimaldi P, Piscitelli D, Albanesi C, et al. Identification of 3′,5′-cyclic adenosine monophosphate-inducible nuclear factors binding to the human urokinase promoter in mouse Sertoli cells. Mol. Endocrinol. 1993;7:1217-1225
52. Nerlov C, De Cesare D, Pergola F, et al. A regulatory element that mediates co-operation between a PEA3-AP-1 element and an AP-1 site is required for phorbol ester induction of urokinase enhancer activity in HepG2 hepatoma cells. EMBO J. 1992;11:4573-4582
53. Wang W, Abbruzzese JL, Evans DB, et al. Overexpression of urokinase-type plasminogen activator in pancreatic adenocarcinoma is regulated by constitutively activated RelA. Oncogene 1999;18:4554-4563
54. Aguirre-Ghiso JA, Frankel P, Farias EF, et al. RalA requirement for v-Src- and v-Ras-induced tumorigenicity and overproduction of urokinase-type plasminogen activator: involvement of metalloproteases. Oncogene 1999;18:4718-4725
55. Sheng H, Shao J, O'Mahony CA, et al. Transformation of intestinal epithelial cells by chronic TGF-β1 treatment results in downregulation of the type II TGF-β receptor and induction of cyclooxygenase-2. Oncogene 1999;18:855-867
56. O'Mahony CA, Beauchamp RD, Albo D, et al. Cyclooxygenase-2 alters transforming growth factor-beta 1 response during intestinal tumorigenesis. Surgery 1999;126:364-370
57. Schwarte-Waldhoff I, Klein S, Blass-Kampmann S, et al. DPC4/SMAD4 mediated tumor suppression of colon carcinoma cells is associated with reduced urokinase expression. Oncogene 1999;18:3152-3158
58. Berger DH, Feng X-H, Yao J, et al. Resistance to transforming growth factor-beta occurs in the presence of normal SMAD activation. Surgery (in press)